TERT promoter mutations and TERT MRNa but not FGFR3 mutations are urinary biomarkers in han chinese patients with urothelial bladder cancer

Oncologist

Volumn 20, Issue 3, 2015, Pages 263-269

  Wang, Kun ^a,b   Liu, Tiantian ^a   Liu, Cheng ^a   Meng, Yan ^a   Yuan, Xiaotian ^b   Liu, Li ^a   Ge, Nan ^b   Liu, Jikai ^a   Wang, Chang ^b   Ren, Hongbo ^a   Yan, Keqiang ^a   Hu, Sanyuan ^a   Xu, Zhonghua ^a   Fan, Yidong ^a   Xu, Dawei ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FGFR3; Telomerase; TERT; Urinary markers; Urothelial bladder cancer

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; FGFR3 PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER SURGERY; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE MUTATION; HAN CHINESE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; URINALYSIS; UROTHELIAL BLADDER CANCER; VERY ELDERLY; ADENOCARCINOMA; BLADDER TUMOR; CHINA; ETHNOLOGY; GENETICS; MUTATION; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; URINE;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, TRANSITIONAL CELL; CHINA; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TELOMERASE; URINARY BLADDER NEOPLASMS;

EID: 84925452904     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0391     Document Type: Article

References (46)

1. Griffiths TR. Current perspectives in bladder cancer management. Int J Clin Pract 2013;67: 435–448.
2. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012;498:135–146.
3. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011;21: 349–353.
4. Kong F, Zheng C, Xu D. Telomerase as a “stemness” enzyme. Sci China Life Sci 2014;57: 564-570.
5. Harley CB.Telomerase and cancer therapeutics. Nat Rev Cancer 2008;8:167-179.
6. Hiyama E, Hiyama K. Telomerase as tumor marker. Cancer Lett 2003;194:221-233.
7. Chiu JW, Wong H, Leung R et al. Advanced pancreatic cancer: Flourishing novel approaches in the era of biological therapy. The Oncologist 2014; 19:937-950.
8. Lamarca A, Barriuso J. Urine telomerase for diagnosis and surveillance of bladder cancer. Adv Urol 2012;693631.
9. Sanchini MA, Gunelli R, Nanni O. et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA 2005;294:2052-2056.
10. Suzuki T, Suzuki Y, Fujioka T. Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. J Urol 1999;162: 2217-2220.
11. Weikert S, Krause H, Wolff I et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005;117:274-280.
12. Yoshida K, Sugino T, Tahara H et al.Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-369.
13. Liu T, Wang N, Cao J et al.The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 2014;33:4978-4984.
14. Kinoshita H, Ogawa O, Kakehi Y et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-730.
15. Neves M, Ciofu C, Larousserie F et al. Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection. J Urol 2002;167: 1276-1281.
16. Heine B, Hummel M, Müller M et al. Nonradioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine. J Pathol 1998;184:71-76.
17. Ito H, Kyo S, Kanaya T et al. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 1998;4:1603-1608.
18. Kavaler E, Landman J, Chang Y et al. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-714.
19. Horn S, Figl A, Rachakonda PS et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-961.
20. Huang FW, Hodis E, Xu MJ et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-959.
21. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367-369.
22. Killela PJ, Reitman ZJ, Jiao Y et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110:6021-6026.
23. Wu S, Huang P, Li C et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: A genomic and molecular study. Eur Urol 2014;65:274-277.
24. Rachakonda PS, Hosen I, de Verdier PJ et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification byacommon polymorphism. ProcNatl Acad Sci USA 2013;110:17426-17431.
25. Wang K, Liu T, Liu L et al. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget 2014;5: 1829-1836.
26. Wang N, Liu T, Sofiadis A et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 2014;120:2965-2979.
27. Liu X, Wu G, Shan Y et al. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013;12:1637-1638.
28. Allory Y, Beukers W, Sagrera A et al.Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-366.
29. Liu T, Brown TC, Juhlin CC et al.The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer 2014;21:427-434.
30. Xie H, Liu T, Wang N et al. TERT promoter mutations and gene amplification: Promoting TERT expression in Merkel cell carcinoma. Oncotarget 2014;5:10048-10057.
31. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target. World J Urol 2007;25:581-593.
32. Kompier LC, van der Aa MN, Lurkin I et al.The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 2009;218:104-112.
33. Lamy A, Gobet F, Laurent M et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006;176: 2686-2689.
34. Lindgren D, Gudjonsson S, Jee KJ et al. Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer 2008;8:183.
35. Wallerand H, Bakkar AA, de Medina SG et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: Contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005;26:177-184.
36. van Kessel KE, Kompier LC, de Bekker-Grob EW et al. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: A comparison of 3 strategies. J Urol 2013;189:1676-1681.
37. van Oers JM, Zwarthoff EC, Rehman I et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009;55:650-657.
38. van Rhijn BW, Lurkin I, Radvanyi F et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61:1265-1268.
39. Jebar AH, Hurst CD, Tomlinson DC et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-5225.
40. Dodurga Y, Tataroglu C, Kesen Z et al. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res 2011;10:86-95.
41. Miyake M, Sugano K, Sugino H et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010;101:250-258.
42. Rieger-Christ KM, Mourtzinos A, Lee PJ et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003;98:737-744.
43. Hernandez S, Lopez-Knowles E, Lloreta J et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-3671.
44. Frantzi M, Makridakis M, Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 2012;22:390-396.
45. Bravaccini S, Sanchini MA, Granato AM et al. Urine telomerase activity for the detection of bladder cancer in females. J Urol 2007;178:57-61.
46. Bodoor K, Ghabkari A, Jaradat Z et al. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol 2010;34:724-732.